Cancer Communications

Papers
(The H4-Index of Cancer Communications is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Global patterns of breast cancer incidence and mortality: A population‐based cancer registry data analysis from 2000 to 2020368
Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020339
Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy327
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021299
LncRNA‐mediated posttranslational modifications and reprogramming of energy metabolism in cancer257
Cancer burden of major cancers in China: A need for sustainable actions250
A nomogram for predicting overall survival in patients with low‐grade endometrial stromal sarcoma: A population‐based analysis187
Ferroptosis in cancer and cancer immunotherapy171
Emerging role of deep learning‐based artificial intelligence in tumor pathology168
EMT‐associated microRNAs and their roles in cancer stemness and drug resistance148
Boron neutron capture therapy: Current status and future perspectives128
Non‐small cell lung cancer in China122
The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma121
CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target111
Single‐cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy104
The FTO/miR‐181b‐3p/ARL5B signaling pathway regulates cell migration and invasion in breast cancer104
Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review102
The role of the HIF‐1α/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer96
Advancing to the era of cancer immunotherapy85
A global assessment of recent trends in gastrointestinal cancer and lifestyle‐associated risk factors80
New insights into the interplay between long non‐coding RNAs and RNA‐binding proteins in cancer76
Tumor‐associated macrophages in liver cancer: From mechanisms to therapy73
Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase 72
Aberrant translation regulated by METTL1/WDR4‐mediated tRNA N7‐methylguanosine modification drives head and neck squamous cell carcinoma progression69
Breast cancer: an up‐to‐date review and future perspectives67
Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine67
Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art66
Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma65
Essential roles of exosome and circRNA_101093 on ferroptosis desensitization in lung adenocarcinoma61
The role of non‐coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential58
New insights into molecules and pathways of cancer metabolism and therapeutic implications55
Cancer‐associated fibroblasts in breast cancer: Challenges and opportunities54
Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy47
Multifunctional inorganic nanomaterials for cancer photoimmunotherapy46
Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells46
Clinical characteristics and survival of 5283 esophageal cancer patients: A multicenter study from eighteen hospitals across six regions in China43
HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5‐WDR5‐dependent transcriptional program42
N‐acetyltransferase 10 promotes colon cancer progression by inhibiting ferroptosis through N4‐acetylation and stabilization of ferroptosis suppressor protein 1 (FSP1) mRNA42
Mex3a promotes oncogenesis through the RAP1/MAPK signaling pathway in colorectal cancer and is inhibited by hsa‐miR‐6887‐3p41
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives41
Clinical utility of Epstein‐Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma40
Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges40
0.088699102401733